Literature DB >> 9578308

Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation.

V L Grandage1, J M Cornish, D H Pamphilon, M N Potter, C G Steward, A Oakhill, D I Marks.   

Abstract

Graft failure is a common and severe complication of unrelated donor bone marrow transplantation (UD-BMT). However, there are few reports of a second UD-BMT in this setting. We describe 12 patients with graft failure (five primary, seven secondary) who had a second transplant, five from their original donor and seven from a different donor. Their median age was 9 years. Two patients died before day 10 of regimen-related toxicity. Nine of 10 evaluable patients engrafted in a median of 17 days. Secondary graft failure was seen in one patient. Transplant-related morbidity was significant. Six of nine developed acute GHVD, there were five severe infections and five patients developed Bearman grade 3 or 4 extramedullary toxicity. Overall, five patients survive at a median of 38 months after the second BMT and two are in continuous complete remission. Second transplants from unrelated donors for graft failure can result in prolonged survival.

Entities:  

Mesh:

Year:  1998        PMID: 9578308     DOI: 10.1038/sj.bmt.1701146

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Second unrelated donor hematopoietic cell transplantation for primary graft failure.

Authors:  Jeffrey Schriber; Manza-A Agovi; Vincent Ho; Karen K Ballen; Andrea Bacigalupo; Hillard M Lazarus; Christopher N Bredeson; Vikas Gupta; Richard T Maziarz; Gregory A Hale; Mark R Litzow; Brent Logan; Martin Bornhauser; Roger H Giller; Luis Isola; David I Marks; J Douglas Rizzo; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-19       Impact factor: 5.742

2.  Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.

Authors:  J Bolaños-Meade; L Luznik; M Muth; W H Matsui; C A Huff; B D Smith; M Y Levy; Y L Kasamon; L J Swinnen; J D Powell; R A Brodsky; R F Ambinder; R J Jones; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-11-03       Impact factor: 5.483

3.  Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT.

Authors:  J A Park; K N Koh; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo; H J Im
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

4.  Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.

Authors:  Gabriela Rondón; Rima M Saliba; Issa Khouri; Sergio Giralt; Kawah Chan; Elias Jabbour; John McMannis; Richard Champlin; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2008-08       Impact factor: 5.742

5.  Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.

Authors:  Boglarka Gyurkocza; Thai M Cao; Rainer F Storb; Thoralf Lange; Wendy Leisenring; Georg N Franke; Mohamed Sorror; Richard Hoppe; David G Maloney; Robert S Negrin; Judith A Shizuru; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

6.  Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.

Authors:  Yu-Qian Sun; Yu Wang; Feng-Rong Wang; Chen-Hua Yan; Yi-Fei Cheng; Yu-Hong Chen; Yuan-Yuan Zhang; Ting-Ting Han; Wei Han; Pan Suo; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-04

7.  Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients.

Authors:  Heiko-Manuel Teltschik; Frank Heinzelmann; Bernd Gruhn; Tobias Feuchtinger; Patrick Schlegel; Michael Schumm; Bernhard Kremens; Ingo Müller; Martin Ebinger; Carl Philipp Schwarze; Hellmut Ottinger; Daniel Zips; Rupert Handgretinger; Peter Lang
Journal:  Br J Haematol       Date:  2016-06-24       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.